Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low-dose 500 mg Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer (mCRPC) and Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Patients: a Phase I Proof-of-concept Clinical Study

NCT06193993 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT06193993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06193993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low-dose 500 mg Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer (mCRPC) and Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Patients: a Phase I Proof-of-concept Clinical Study
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 30, 2021
Completion date
September 30, 2026
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, hormone sensitive prostate cancer, metastatic cancer, prostate cancer